Search

1. Labs with questionably high billing for additional tests alongside COVID-19 tests warrant further scrutiny

Author(s):

Maxwell, Ann, (Deputy Inspector General for Evaluation and Inspections), author

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Clinical Laboratory Techniques -- economics
Costs and Cost Analysis
COVID-19 Testing -- economics
Insurance, Health, Reimbursement
Medicare Part B
United States

2. Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2022

Subject(s):

Data Analysis
Drug Costs
Government Regulation
Medicare Part B
United States

3. CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Cost Control
Drug Costs
Drug Industry
Government Regulation
Medicare Part B
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

4. Manufacturers may need additional guidance to ensure consistent calculations of average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Drug Costs
Drug Industry
Government Regulation
Medicaid
Medicare Part B
Prescription Fees
United States

5. Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, August 2023

Subject(s):

Cost Control
Drug Costs
Government Regulation
Medicare Part B
Prescription Fees
United States

6. Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, February 2023

Subject(s):

Drug Costs
Government Regulation
Inflation, Economic
Medicare Part B
United States